PODD
Insulet CorporationNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
58.21
PEG
—
P/B
9.49
P/S
5.31
EV/EBITDA
30.25
DCF Value
$-29.01
FCF Yield
2.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
71.6%
Operating Margin
17.5%
Net Margin
9.1%
ROE
17.4%
ROA
8.2%
ROIC
13.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $783.8M | $101.6M | $1.44 |
| FY 2025 | $2.71B | $247.1M | $3.48 |
| Q3 2025 | $706.3M | $87.6M | $1.24 |
| Q2 2025 | $649.1M | $22.5M | $0.32 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.47
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.